Safety of Prasaprohyai 95%Ethanolic Extract Capsules in Healthy Volunteer

NCT ID: NCT03077282

Last Updated: 2019-06-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-26
• Study Completion Date: 2018-12-14

Brief Summary

To investigate the safety of Prasaprohyai 95% ethanolic extract at doses of 100 mg and 200 mg for for 6 weeks. (Clinical Trial phase I)

Detailed Description

Sample size Group 1 (100mg/meal) = 6 female, 6 male Group 2 (200mg/meal) = 6 female, 6 male

Volunteers will be divided into 2 groups. One will take Prasaprohyai 95% ethanolic extract capsules at a dose of 100 mg three times a day before meals and the other take Prasaprohyai 95% ethanolic extract capsule at a dose of 200 mg 3 times a day before meals for six weeks. After that, they will cease using the drug for 2 weeks (wash out period). All volunteers will be followed up in the third week, sixth week and eighth week to evaluate the safety of the medicines. The researcher will record data such as age, career, BMI, vital signs, signs and symptoms. Safety will be monitored by hematology tests such as liver function test, renal function test, lipid profile and blood sugar.

The first step in this research will be to study group 1 (100 mg). If it proves safe, the group 2 (200 mg) will be studied.

The data gathered will be evaluated using statistical software. The results are in the form of mean ± standard deviation. The study will be planned as repeated measured ANOVA or Friedman's test in order to evaluate differences between groups, accompanied by using paired t-test or Wilcoxon's test in order to evaluate differences within groups. A significance level of p < 0.05 will be considered statistically significant.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

group1

Group1 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 100 mg three times a day before meals (for 6 weeks)

Group Type: EXPERIMENTAL

Prasaprohyai

Intervention Type: DRUG

Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals

group2

Group2 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 200 mg three times a day before meals (for 6 weeks)

Group Type: EXPERIMENTAL

Prasaprohyai

Intervention Type: DRUG

Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals

Interventions

Prasaprohyai

Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1) Age in range 20-60 years old.
• 2) Healthy, or don't have serious medical conditions such as congestive heart disease, liver and renal dysfunction, uncontrolled hypertension, severe asthma, tuberculosis, HIV in the previous month before being recruited in the study, using history taking and complete physical examination and laboratory result.
• 3) Do not taking a medicine constantly.
• 4) Female not pregnant or lactating (non menopause woman will have a pregnancy test. Time since first day of last menstruation 28-35 days).
• 5) Participant and agreement to follow the instructions for 8 weeks.
• 6) Not a participant in another study.

Exclusion Criteria

• 1) Allergic reactions to Prasaprohyai medications.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Thai Traditional Medical Knowledge Fund

OTHER_GOV

Sponsor Role: collaborator

Thammasat University

OTHER

Sponsor Role: lead

Responsible Party

Miss Nichamon Mukkasombut

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Thammasat university

Khlong Luang, Changwat Pathum Thani, Thailand

Countries

Thailand

Other Identifiers

MTU-EC-TM-4-137/59

Identifier Type: -

Identifier Source: org_study_id